205
Views
4
CrossRef citations to date
0
Altmetric
Research Articles

Arylidene analogues as selective COX-2 inhibitors: synthesis, characterization, in silico and in vitro studies

, , , &
Pages 7150-7159 | Received 30 Apr 2020, Accepted 31 Jul 2020, Published online: 14 Aug 2020
 

Abstract

Pyrazole derivatives are known to be as non-steroidal anti-inflammatory drugs (NSAID). Celecoxib is the pioneer sulfonamide being pyrazole derivative COX-2 inhibitors, which used to treat pain and inflammation; they may also have a role in cancer prevention. In the present investigation, a series of arylidene analogues (NDP-4011 to NDP-4016) were synthesized by the condensation of 4-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl) benzenesulfonamide (I) with various substituted aromatic aldehydes in ethanol using a catalytic amount of piperidine. All the synthesized compounds were well characterized by IR, 1H NMR, 13C NMR and mass spectrometry. The cytotoxicity of synthesized compounds was tested on the NRK-52E cell line. From which NDP-4011, NDP-4012, NDP-4013, NDP-1015 and NDP-4016 were found to have higher cytotoxicity whereas NDP-4014 showed less cytotoxicity compared to Celecoxib. The in silico pharmacokinetic parameters of compounds were evaluated to check their candidature as a drug. Molecular docking was carried out on COX-2 structures, which revealed that NDP-4011 to NDP-4016 targets allosteric binding site similar to the binding mode of the selective COX inhibitor Celecoxib. Furthermore, results of in vitro COX-2 inhibition assay supports arylidene analogues as COX-2 inhibitors.

GRAPHICAL ABSTRACT

Communicated by Ramaswamy H. Sarma

Acknowledgements

Dipti L. Namera is thankful to FIST-DST and SAP-UGC for instrumentation support and MSME Foundation for financial support as a project fellow for ‘Facility for Preservation of Molecular Diversity’ (FPMD) project. Special thanks to ‘National Facility for Drug Discovery through New Chemical Entities (NSE) Development & Instrumentation Support to Small Manufacturing Pharma Enterprises’ Programme under and Pharma Research Support (DPRS) jointly funded by Department of Science & Technology, New Delhi, Government of Gujarat Industries Commissionerate & Saurashtra University, Rajkot.

Disclosure statement

The authors declare that they have no conflict of interest.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 61.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,074.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.